Ancestry Kit_Living_DNA_Shivom

Shivom Adds Living DNA to the Marketplace, Offering Customers a 3-in-1 Ancestry Kit

Ancestry Kit_Living_DNA_Shivom

Living DNA’s 3-in-1 ancestry kit will provide Shivom’s customers with the ability to trace their origins back via maternal ancestors, and see how they moved around the world over thousands of years.

London, United Kingdom – April 15, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has teamed up with Living DNA. This is a collaboration of over 100 world-leading scientists, academic researchers and genetic experts from across the globe with the purpose of bringing cutting edge DNA technology to the world; to offer Living DNA’s 3-in-1 ancestry kit within Shivom’s marketplace. Through this affiliation, Shivom’s customers can discover their ancestral journey across 80,000 years.

The ancestry kit which has been developed by Living DNA enables consumers to discover their ancestry from around the world via a simple cheek swab, providing exceptional regional details. Many of their customers have used this opportunity to travel to their ancestral homelands. Living DNA can show you your recent family ancestry covering up to 15 generations, and your deep ancestry with Motherline and Fatherline (if male) results. Additionally, the company have developed an improved Single nucleotide polymorphisms (SNP) genotyping platform that has been tailored to match the technical requirements of the different statistical methodologies they use to analyse customer data. Sirius, the new chip, has been designed using the Axiom® technology from Affymetrix / Thermo Scientific, which allows great flexibility to match every feature of the chip to their products.

To mark this milestone and affiliation, for a limited period of time, Shivom plans to offer incentives including; token rewards and discounted genetic counselling sessions via Family Care Path’s MyLegacy application.  This offer is for the first batch of customers who purchase the 3-in-1 ancestry kit from the Marketplace and subsequently upload their genetic data onto Shivom’s platform. “We are excited to offer Living DNA’s kits within our marketplace. Living DNA, along with parent company DNA Worldwide Group, shares the same high standards of excellence and commitment to consumer data ownership and security as Shivom. Living DNA’s kit is not only rated one of the best ancestry kits on the market, but they are also accredited and certified by leading international standards.” Says Henry Ines, CEO of Shivom.

For more information about Shivom please visit:
https://www.shivom.io

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Living DNA
Living DNA is a high definition of DNA testing that challenges the concept of race and tackles ideas of separation through our ‘One Family, One World’ education programmes. With 75% of clients living overseas, we do this globally.

Presenting self-truth and letting science talk helps people change their lives. Putting ancestry into context allows people to celebrate not only how unique they are but also understand how we are all connected going back through history.

For more information about Living DNA please visit:
www.livingDNA.com

Recommended

Cleveland Clinic-Family-Care-Path-Shivom

Shivom Partners with Family Care Path a Spin-Off Company from Cleveland Clinic

Cleveland Clinic-Family-Care-Path-Shivom

Family Care Path’s clinically-validated MyLegacy and CarePathConnect application will provide new ways for Shivom’s customers to take action on their genetic risk for certain hereditary conditions.

London, United Kingdom – April 2, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and Family Care Path (FCPI), a spin-off company from Cleveland Clinic adapting and marketing web-based clinical decision support applications, are collaborating to integrate FCPI’s MyLegacy application within Shivom’s marketplace. Through collaboration, Shivom’s customers can gain access to a personalised health risk profile and genomic counselling sessions which provide end-users with coaching to take proactive steps against hereditary conditions found within their genetic data.

FCPI has established an international telegenetic counselling network, branded CarePathConnect, which provides patients with the ability to privately and securely discuss their genetic health risk conditions with genetic counsellors and learn about the benefits and limitations of genetic testing via a HIPAA-compliant web-based video platform. The company exclusively licensed the family history collection and disease risk assessment tool from Cleveland Clinic, branded MyLegacy, which uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute.

“Access to your genetic information is really just the beginning — using that information in combination with genetic counselling allows the necessary preventative measures to prevent serious health complications,” said Henry Ines, CEO of Shivom. “Our collaboration with Family Care Path enables Shivom’s customers to access their genetic information using a clinically validated programme to help them make lifestyle changes which seek to prevent or suppress hereditary conditions.”

The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session. Both clinical and non-clinical counselling sessions will be explored and processes will be established to ensure that customers are able to utilise both data collected from the FCP risk assessment tool as well as any genomic or other ‘omics’ reporting facilitated by Shivom subject to patient consent and permissions. Shivom also plans to arrange for its OMX token to be utilised as a means of payment and incentives for accessing counselling sessions and related services. The partnership marks a critical step in the roadmap for Shivom as it onboards key partners and services on its platform/marketplace to further demonstrate utility for its token.

“We are excited to collaborate with Shivom on this innovative effort. Working with Shivom will help their customers have a deeper understanding of their genetic information through testing, counselling and the ties to family health history” says David McKee, President and CEO of Family Care Path.

For more information about Shivom’s direct-to-consumer solutions please click here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Announcements
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilising industry standard protocols, to enable widespread adoption.

We utilise the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:
www.familycarepath.com

Recommended

Shivom-Alpha-2.0-Release

Shivom Releases Alpha 2.0 to Genomic Researchers & Data Owners

Shivom-Alpha-2.0-Release

Shivom – a data discovery and analysis solutions platform – on Tuesday unveiled its second release – Alpha 2.0. Leveraging the latest advancements in blockchain and machine-learning technology, Shivom is optimising how DNA is shared, secured and analysed in order to bring exponential value to the genomics industry.

In November 2018, Shivom launched its first release amid great enthusiasm and fervour. Since then, the product and development teams have been working on fixing bugs and integrating new features that have come from their recent partnership with Lifebit. In its first release, it streamlined its UI/UX and USPs based on the need to innovate in the area of secure storage. It also had multiple new-age features such as simplified sign-up DNA upload & encryption, etc.

Continuing its efforts in the area of innovation, Shivom continued developing on the previous release and has now launched its second release – Alpha 2.O. The latest advancements in the platform include avatars, issuing of notifications, bug-fixing throughout the platform, enterprise search functionality, an upgraded UI, and finally our blockchain transaction and verification for DNA file-uploading.

With the above-mentioned substantial updates, the platform can now verify via blockchain when a file is uploaded, secured and encrypted via Shivom. The next release titled ‘MVP’ will set to deliver DNA sequencing kits, an integrated wallet, marketplace and secure-sharing features. With a successful and well-tested second release, Shivom is steering itself into capturing a mega segment in this market.

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies and pharmaceutical companies with the ability to securely share, store and analyse DNA data quickly, efficiently and at any scale. such as blockchain and machine-learning algorithms, we are able to democratise genomics. Doing so, we empower data-owners, researchers To learn more about the project, visit the Shivom website.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Community
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

Recommended

Decentralized DNA Storage Mechanism for Healthcare

Harnessing Blockchain Technology to Lay the Foundation for Tomorrow’s DNA Ecosystem.

The flexibility of blockchain infrastructures has captivated innovators, entrepreneurs and developers across a number of verticals (more so than ever in the past year). Many are beginning to truly appreciate the properties that make distributed ledger technologies so valuable, notably where data security is concerned.

Blockchains are perhaps best described, in simple terms, as append-only databases that are controlled by a consensus mechanism made up of numerous participants (without a hierarchy or centralized overseer). Compared to a traditional database, this means that there is no central point of failure for an attacker to target. The participants in question will each maintain a copy of this ledger, synchronizing it with that of their peers when a ‘block’ (chunk of data) is added to the network.

This may not seem particularly exciting at first glance, but it is, in fact, a very powerful tool — each block added to the ledger is cryptographically linked to the prior one, meaning that any attempt to alter the information will be automatically rejected by the rest of the participants. As such, blockchains are often touted as being immutable and tamper-proof.

The security of such networks stems from this structure, the topology at the peer-to-peer level and the use of robust cryptography (private/public keypairs) to ensure that only the individual uploading data can decrypt it or demonstrate ownership.

Towards Medical Applications

Home genetic testing has been garnering a lot of attention from consumers recently as services like Ancestry or 23AndMe have cropped up to provide insights into the health of the user — at the cost, of course, of the sharing of genomic data.

It’s hard to imagine a source of data more personal to an individual than their genetic information. It stands to reason that it’s crucial that said data is kept both secure and private — easier said than done in an age of digitization of information, home DNA testing kits and rampant data breaches.

Most companies go to lengths to anonymized your data before sharing it, and to keep it secure. But sharing this type of sensitive personal information comes with an inherent risk. Consumer genetic testing firms are not typically bound by HIPAA, which means the flow of personal information is completely unregulated. And the more places data flows, the more chances there are for it to leak.

Blockchain technology may initially seem ideally suited to these ends, though it’s just a partial solution — one of the trade-offs of an immutable distributed ledger is that its throughput is somewhat lacking (remember that every participant must record every interaction), and storing even small amounts of data is an expensive and time-consuming task.

Evidently, in designing a platform for mass adoption, a sort of hybridized approach is best. Leveraging the features of blockchain technology and combining it with more scalable storage mediums, vastly superior alternatives to the existing ‘data silo’ phenomenon can be built. With such alternatives, secure repositories of data that are controlled entirely by the individual are anchored in the blockchain, which provides an unalterable record of the interactions occurring across the network.

True Self-Sovereignty

Third-party custodians and data security are not concepts that go hand-in-hand. We’ve seen the catastrophic consequences that breaches like that of Equifax and Facebook can have on the lives of their victims. It’s not something that can be allowed to continue in transitioning masses of genetic information into the digital realm. DNA is not as easily changed as a username/password.

With a tech stack built on top of a blockchain, we can reverse some of the damaging patterns that have emerged as a result of a trust-heavy data ecosystem, putting individuals wholly back in control of information that belongs to them in the first place. Though the concept of an entirely ‘self-sovereign identity’ has existed for a couple of decades now, we’re finally beginning to perfect the technologies that would make truly private and secure interactions in the digital space possible.

Find out more by following us on Twitter:

Recommended

World Sprint Champion Lion Martinez Joins Shivom Innovation Council

The M35 100-metre world sprint champion Lion Martinez joined Shivom Innovation Council (SIC) on February 1, 2019. Shivom is a biotechnology data and analysis company optimizing the way DNA is shared, secured and analysed. It leverages innovative technologies such as blockchain and machine-learning algorithms to democratize genomics.

Lion joining SIC marks the very first steps of Shivom into building a sport, athletics and well being initiative. The sports initiative will use state-of-the-art genomics and AI algorithms to develop science-based programs to make people fitter and perform on a higher level. The program seeks to identify from genetic bases as to what makes an athlete an, in turn, this data into meaningful insight for sports and fitness individuals who are interested in trying innovative and evidence-based training programs to improve their efficiencies. With his experience in athletics, Lion will play a key role in strategizing on the same.

SIC is an internal think tank at Shivom which supports and guides the senior management on the latest technologies, industry trends and strategies. It includes expert scientists, groundbreaking healthcare solution-providers, cyber security pioneers and genomics researchers. The council includes the likes of Taavi Roivas, former prime minister of Estonia and Antanas Guoga, a Lithuanian representative at the European Parliament. With Lion coming onboard, Shivom plans to foray into sports and well being soon.

Lion, who in his own words “likes cooking, gaming and toast”, has 20 years of experience in marketing, and brand and product management. He professional endeavours include working in various capacities with global companies such as Electronic Arts, Disney, Warner Brothers, Asus and Sony, among several others. Lion is presently the Global Product Manager of e-sport software company Wasder AB.

A former national and European-level athlete, Lion has numerous national gold medals (in 100-metre sprint) in his kitty. He was also the youngest-ever Swedish to have participated in the 2002 European Championships in Munich. Lion holds a 100-metre world championship gold medal (2016) and has numerous records and medals (in 60, 100 and 200-metre sprints) to his credit. Additionally, he has been involved in coaching, public speaking and widespread health issues and initiatives over the past 20 years, engaging with children, youth, adults and senior citizens alike. We believe he will become the torchbearer of the planned sports initiatives at Shivom.

About Shivom
Shivom is a biotechnology data and analysis company optimizing the way DNA is shared, secured and analysed. By utilizing innovative technologies such as blockchain and machine-learning algorithms, we are able to democratize genomics. Doing so, we empower data-owners, researchers and pharmaceutical companies with the ability to securely share, store and analyse DNA data quickly, efficiently and at any scale. For further information, please visit: https://www.shivom.io/

Recommended

The Cervical Cancer Awareness Month is here! How aware are you

Cervical Cancer Awareness Month is here! How aware are you?

The Cervical Cancer Awareness Month is here! How aware are you

How often have you come across a patient of cervical cancer around you? Chances are, rarely. But reality begs to differ. According to the World Health Organization (WHO), over six per cent women around the world (including 570,000 new cases) suffered from cervical cancer in 2018. Sadly, the statistics of both the developed and developing countries tell a similar horrifying story. Every day, nine women in the UK are diagnosed with cervical cancer and three lose their battles to life. In the US, nearly 13,000 women are diagnosed with cervical cancer every year, which amounts to an appalling 36 women falling prey every day! Developing countries like India have morbid statistics too. As per a study by National Center for Biotechnology Information, India alone accounts for a quarter of cervical cancer cases globally. Approximately 270,000 women across the world die from cervical cancer yearly, with 85 per cent deaths occurring in low-to-middle income countries. Owing to the gigantic figures, the United States Congress designated January as the Cervical Health Awareness Month.

Most common among women aged around 35 years, cervical cancer has remained, through times, an ignominious reality. However, even more lamentable is the fact that 75 per cent of such cases are actually prevented by cervical screening (or smear tests) and vaccination. Yet, one in four women does not attend this potentially life-saving test because of embarrassment. Some time back as part of the Pink Chain campaign, a study among schoolteachers in India was conducted. It revealed that cervical cancer was the second most common cancer in India. It also identified and assessed the level and impact of awareness programs in the adoption of safe practices in prevention and early detection. Uneasiness around discussing the topic with friends, family and peers emerged as the main reason behind women not coming forward for tests and treatment.

While cervical cancer rates have dropped significantly within the United States over the past few decades, it still remains a critical global health issue. The high mortality rate for cervical cancer in the developing world is driven by limited access to cervical cancer screening and treatment. Laboratory-based methods used to detect cervical cancer, and the personnel required to perform and analyse them may be unavailable in developing nations. In an alarming finding, it was identified that approximately 90 per cent of deaths from cervical cancer occurred in low- and middle-income countries. Likewise, the ability to treat cervical cancer is highly dependent on access to surgical facilities, chemotherapy agents and radiation equipment.

The high global mortality rate despite having mechanisms to diagnose and treat this cancer is a matter of great concern. Doctors and researchers have time and again emphasized that more awareness programs need to be run and sustained in order to literate people, especially women, to combat this cancer. Women must be encouraged to speak, walk up to a doctor and get her diagnosed. Reduction in mortality could be induced through a comprehensive approach which includes preventive care, early diagnosis, effective screening and treatment, and follow-ups. Particularly, in countries where screening programs are not available, identifying cervical cancer at an early stage and providing effective treatment can improve the likelihood of survival. Presently, in many low-income nations, the disease is often not identified until in advanced stages.

Widespread training and awareness programs run by state governments in partnership with CSR divisions of private firms can also be a way forward in combating cervical cancer. They must be made educated on the initial symptoms of the cancer. WHO Package of Essential non-communicable (PEN) disease interventions for primary healthcare in low-resource settings has guidance on the approach to assessing and referring affected women in the primary care setting. This must be widely publicized through various broadcast channels. In one of its studies, the WHO has concluded that “… screening should be performed at least once for every woman in the target age group (30-49 years) when it is most beneficial; HPV testing, cytology and visual inspection with acetic acid (VIA) are all recommended screening tests;  cryotherapy or loop electrosurgical excision procedure (LEEP) can provide effective and appropriate treatment for the majority of women who screen positive for cervical pre-cancer; “screen-and-treat” and “screen, diagnose and treat” are both valuable approaches.”

Irrespective of the approach being deployed in educating women, the key to an effective program is reaching the largest proportion of women at risk. Organized screening programs, comprehensive cervical cancer prevention and control, community education, social mobilization, vaccination, etc. can go a long way in improving cervical cancer control. Cervical Health Awareness Month is an opportunity to dedicated work, for a whole month, towards ensuring that our women remain safe and prevented from this deadly cancer. Let us spread the word around, not only among our female friends but also among our male friends, peers and family so that in case of such diagnosis, every person around must be aware of the next critical steps involved in treating the patient. Let us all be well-equipped for a better tomorrow because prevention is certainly better than cure.

Recommended

End of Year Roundup

As 2018 draws to a close, the team at Shivom are incredibly proud of what we’ve accomplished in the past year, and look forward to progressing in our mission to build the world’s largest blockchain-based genomic data hub for years to come.

As those who have been supporting us know, we’ve come a long way from where we were this time last year. After closing an incredibly successful ICO, we’re proud to say that the OMX token is listed on four exchanges. We’ve assembled an impressive team and Innovation Council, restructured, the company’s leadership, redesigned our website and forged important partnerships, opened up an office in London, all whilst continuing to fine-tune the Shivom platform – in case you missed it, we released the Alpha last month, allowing users to securely upload DNA data and create a wallet which, beginning in Q1 2019, will allow them to monetize the sharing of this information with researchers and institutions.

You can look forward to a handful of other updates around that time. Our next release will integrate features such as Enterprise Search and analytic tools for pharmaceutical and healthcare organizations, to name a few.

In our ongoing goal to contribute to the fields of predictive and preventative medicine, Shivom in coordination with local partners have commenced with the development of clinical research pilot projects focused on the collection of  DNA samples from those afflicted with sickle-cell disease and type-2 diabetes (in Sub-Saharan Africa and India, respectively). Both of these diseases are rampant in these regions, and while modern technologies allow for their diagnoses, they often go unnoticed. Alongside our partners,  Genetic Technologies Limited, eMQT, and the local partners in India, we’ll rely on the Shivom platform to collect and store genomic information securely, before sequencing and analysing it, allowing researchers to devise better and more affordable treatments, both globally and in specific regions.  Other partnerships formed this year include MeFy, Atana and SingularityNET both pioneers in the blockchain space.

In addition to our blockchain partnerships, we’re of course also thrilled to be working closely with our new London-based bioinformatics partner Lifebit. Lifebit are creating a cloud-based cognitive system, leveraging sophisticated machine learning algorithms to allow their software to draw powerful insights from genetic information.

We intend to integrate Lifebit’s ‘Deploit’ pipeline, which will allow users and organizations using the Shivom platform to perform analytics on their data automatically. Its widespread use by R&D departments and other players in healthcare is a testament to the quality of the insights derived from genomic information fed into the system. What this means for Shivom users is highly scalable, highly effective and near-instant analytics around the clocks. Shivom will provide presets for easy use, though tech-savvy users and businesses will have a wide variety of customization options with Docker services.

In other news, we hope you caught the Advancements on CNBC on the 16th of December, where the world of blockchain technology was explored by Ted Danson, with a special feature on Shivom.

In other events, the team have been busy in this last quarter sharing the Shivom story across the globe.  CSO Gourish Singla represented Shivom at the Malta Blockchain Summit and Slush Small Talks, India. COO DR Natalie Pankova and Marketing Director Nate Raine attended HealthCare Unblocked in London.  The penultimate event of the year, the Digital Freedom Festival, saw CEO, Henry Ines give a keynote titled “The Future of Health: Reinvention of Healthcare & Wellness”

Where to find us next

We are already busy with plans for the start of the year with Henry Ines, CEO recently announced our exciting partnership with FMW Media Works, the parent Company of ‘NEW TO THE STREET’ and our appearance on their 12-month TV series ‘EXPLORING THE BLOCK’ which will air on the FOX Business Network. We look forward to sharing our journey to date as a health-tech startup and showcasing our genomics datahub and marketplace powered by blockchain and AI technology.

January will see us travel to Silicon Valley to the Precision Medicine World Congress where are excited to be presenting to the Pharma community. Additionally, Dr Axel Schumacher will also be speaking at the Next Level Life Sciences in Basel.  

It’s been a busy and productive year. We’ve come a long way, and have no intention of slowing down anytime soon. None of our efforts would have been possible without the support of our vibrant community and backers, so we’d like to thank you all profusely for joining us on our mission.

Happy Holidays!

The Shivom Team

Recommended

Shivom Partners With Lifebit

Blockchain genomics pioneer and AI data analysis firm will provide pharmaceutical organizations and life science users with comprehensive reporting through a library of pipelines

London, United Kingdom – 11 December 2018 – Shivom, the blockchain genomics platform that is powering personalized healthcare, has partnered with Lifebit, the AI-powered DNA-analysis firm, to give users unprecedented reporting capabilities for DNA data analysis.

The partnership will mean that immediate Genome Wide Association Study (GWAS) analysis is possible, with no specialist knowledge or in-house data scientist required. It also means that users can access a library of pipelines (ready built software that are used for analysis) and an AI-powered toolkit for analysing the data in a way that is far more scalable than other solutions.

Another aspect that makes the Shivom platform superior to other genomics platforms is that it will give pharmaceutical organizations and life sciencee users the ability to access real-time analysis whenever they need it with no waiting time, no application process for accessing the data and deadlines or cut off dates that restrict their access.

“Through this partnership with Lifebit, we are providing enterprise users with the tools they need to find the right patients for their clinical trials more easily and more accurately than is possible through other solutions. Not only that, it brings AI into GWAS analysis in a way that hasn’t been seen before,” said Dr Axel Schumacher, Co-Founder and Chief Scientific of Shivom.

The use of genomics platforms to improve rare disease treatment has increased in recent months, with 23andMe partnering with GlaxoSmithKline to develop drugs for Parkinson’s. However, the Shivom Lifebit partnership demonstrates a major leap forward in this area because it adds AI and Machine Learning capabilities to the identification of potential patients.

To do this, users will be able to access a library of pipelines within the Shivom platform. These include preset Shivom pipelines, those created through open source software and any that an enterprise chooses to develop using Github and DOCKER services.

“Our partnership with Shivom will allow us to combine unique datasets with a level of analysis automation and insight generation that has never been seen before on a genomics platform,” said Dr. Maria Chatzou, co-founder and CEO of Lifebit. “In this way, scientists and doctors will be able to get all the benefits of this rich database without the need to rely on a data scientist for help. On the other hand, still ensuring that the individuals that have provided data to Shivom are given a level of security and control only a state-of-art blockchain technology can offer.”

The partnership with Lifebit comes with the Shivom platform having already been released in alpha. The full launch of the platform is expected in Q1 2019.

-ends-

Media Contact:
Frances Wells
Cryptoland PR
E: frances@cryptolandpr.com
US: 866–586–5603
UK: +44 020 3908 5686

About Shivom:
Shivom is powering the next era of genomics through blockchain technology – protecting identity, personalizing healthcare and transforming lives. For the first time ever, a precision medicine ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics and associated apps and services to drive personalized medicine. Shivom intends to extend its services to form a global network of associated laboratories and research centres, as well as genetic counsellors and other relevant services.  For further information, please visit: http://35.231.194.138/

About Lifebit
Lifebit is building a cloud-based cognitive system that can reason about DNA data like humans do. This offers researchers/R&D professionals, and their corresponding organizations (ie. pharmas), a highly scalable, modular and reproducible system that automates the analysis processes, learns from the data and provides actionable insights. For further information, please visit: https://lifebit.ai

Recommended

Our Alpha Public Release!

Back in August, we announced that we would be releasing a platform in order for our community to test and give us feedback on the first iteration of our Alpha product.

After onboarding a wealth of new talent and welcoming Henry Ines to the role of CEO, we felt it time to take a step back and reassess our current position. We realized that many of our competitors, both startups in the blockchain space and traditional genetics companies had spent a significant amount of time streamlining their UI/UX and USPs. It became clear to us that we needed to innovate in an area that’s often overlooked – secure storage. In perfecting such a solution, we would be able to offer our community and competitors alike greater freedom and transparency where the storage and sharing of their DNA data is concerned, having a positive knock-on effect on the direct-to-consumer genetic testing industry.

Months of development later, after several scrum meetings and all-nighters, we’re thrilled to unveil to the community the long-awaited Alpha Release!


A Sleek UI/UX Brand Overhaul

Users will also notice that we’ve greatly simplified our sign-up process, stripping it down to three easy steps:

Select whether you’re a consumer or an enterprise user, before adding general account information (name, DOB, country, etc.)

Complete health and wellness information by answering a range of questions (which, in later releases, will not only help us better assess which products we should provide our audience with, but also improve the search function for organizations seeking particular DNA datasets). Of course, the user will be able to specify whether they wish to be ‘discoverable’ in our Enterprise Search feature.

The final step in the sign-up process is adjusting user permissions – you’ll be able to set search, viewing and contact permissions that are linked to DNA data uploaded onto the platform. We’ve implemented toggle functionality to offer users a more granular experience over categories. For instance, they may choose to only make their data searchable and available to academic research teams over governmental organizations.

DNA Upload & Encryption

As aforementioned, we’ve spent countless hours fine-tuning our secure storage feature whilst ensuring newcomers and users of previous genetic testing kits are provided with a seamless experience for securely uploading their data. If you’ve used another testing service previously, all you need is your genetic information to get started – usually, this is stored in a file with a .vcf extension.

Navigate to the MYDNA page and click on ‘Upload’ to select the requisite file from your device. Once selected, it will be encrypted and subsequently stored on the Shivom platform. In successive releases, expect an even simpler process, where logins for sites like 23andMe or Ancestry can be used in order to directly import data.

Additionally, this page allows you to pre-order home testing kits. Select this option to be added to the pre-order list for the kits, which will be shipped in Q1 of 2019.

 

What’s Next?

Shivom will continue iterating on its product and fleshing out our core features – above all, our work is driven with a focus on security and accessibility. In tandem, we’ll launch numerous upgrades to campaign management for enterprise users and our Enterprise Search function (providing granular filters for organizations seeking out specific data sets, i.e. those from specific regions, associated with certain diseases or conditions, etc.).

For users that wish to share their data with researchers or institutes in the medical field (all whilst being remunerated for their participation), we’ll be rolling out the ability to anonymously provide organizations with datasets within a set timeframe, leveraging blockchain-based payments directly into an integrated wallet accessible via Shivom’s web portal.

Stay tuned for more exciting updates on our roadmap, developments and partnerships in the coming weeks. Go ahead and experiment with the Alpha, and be sure to let us know what you like, what could be improved, and what you’d like to see added in the future via the Intercom feature at the bottom right-hand side of the portal.

Until next time,

The Shivom Team

Recommended

World Alzheimer’s Awareness Month

Shivom is helping to make diseases like Alzheimer’s a thing of the past. By creating a secure platform for the storage and sharing of genomic data, Shivom is transforming the precision medicine of tomorrow by allowing researchers and pharmaceutical R&D pipelines access to vital genomic data today. This type of data can help determine an individual’s predisposition to certain diseases, among them Alzheimer’s, and even help in the development of future preventatives and cures.

Shivom’s Chief Scientific Officer, Axel Schumacher published the first proof of whole-genome epigenetic abnormalities in late-onset Alzheimer’s Disease. His report specified that epigenetic drift, or change, that occurs with age may put people at higher risk for developing the disease. The findings suggest that epigenetic drift may be an important driving force in AD pathology and raise the tantalizing question of whether such epigenetic changes could be prevented.

Around the world, 44 million people suffer from Alzheimer’s, a fatal form of dementia. The U.S. is home to 5.5 million of those suffering, among them 200,000 people younger than 65 with early-onset symptoms.

The prevalence of Alzheimer’s increases with each generation, especially as populations live to be older. By 2050, the number of those affected in the U.S. is estimated to quadruple, leaving 14 million with the disease (World Alzheimer Report, 2018).

According to the Center for Disease Control and Prevention, not only are more people getting Alzheimer’s as they age—the disease is becoming deadlier. Between 1999 and 2014, death rates from Alzheimer’s increased 55 percent, and today the disease is the 5th leading cause of death in the U.S. In 2017, caregiving associated with Alzheimer’s cost the U.S. $259 Billion, which is nothing in comparison to the physical and emotional toll the disease takes on its victims and their family members.

Alzheimer’s disease is, paradoxically, unique for both its pervasiveness and its mystery. Despite its ubiquity among U.S. senior citizens, there is still no cure in sight, and much about the disease remains unknown. What clinicians do know is that genetics play a large part in determining an individual’s predisposition to the disease.

The most common gene associated with late-onset Alzheimer’s is the apolipoprotein E (APOE). This gene has three forms: the APOE-e2 variety, which reduces one’s risk for the disease, the APOE-e3 variety, which appears to have no effect on risk, and the APOE-e4 variety or the “Alzheimer’s Gene,” which increases one’s risk.

Every person inherits two APOE genes from their parents—one from their father, and one from their mother. However, inheriting two APOE-e4 genes doesn’t necessarily guarantee that an individual will develop Alzheimer’s. Conversely, some people born without any APOE-e4 genes may also develop the disease. Still, according to a study recently published in Neuron, over 50 percent of Alzheimer’s cases are linked to APOE-e4.

Last year, researchers with the Mayo Clinic also linked APOE-e4 to the newly-termed “Type 3” Diabetes, a form of diabetes in the brain. It’s already well-known that those who suffer from Type 2 Diabetes are more likely to suffer from Alzheimer’s due to reduced blood flow and lack of essential nutrients to the brain. Now, it has been discovered that APOE-e4 interferes with brain cells’ ability to use insulin, causing the cells to starve and die.

Still, clinicians don’t generally test for the APOE genotype among late-onset Alzheimer’s patients. Results can be indeterminate, and the disease can usually be diagnosed without genetic testing by that point.

However, testing early-on for APOE-e4 or other mutant genes associated with early-onset Alzheimer’s, like Amyloid precursor protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2), could help determine with some certainty if an individual will develop the disease before the age of 65.

One common characteristic among those with Alzheimer’s are “amyloid plaques,” which are amyloid-beta peptides that build up in the brain and clump together, leading to the death of nerve cells. As these clumps collect, tau protein malfunctions stick together forming neurofibrillary tangles, creating the types of brain abnormalities commonly associated with Alzheimer’s (Mayo Clinic, 2017).

Imagine how much could be learned about Alzheimer’s through the collection of genomic data worldwide. Researchers could identify more of the unknown genetic mutations that cause amyloid plaques, or even isolate an autosomal dominant gene shared by all Alzheimer’s patients, or sets of genes that increase susceptibility to the disease. This could allow for earlier diagnoses, and perhaps, one day, preventative measures or even a cure.

By creating a secure platform where researchers and pharmaceutical R&D pipelines have access to stored genomic data on a massive scale, Shivom hopes to propel treatment for Alzheimer’s forward, incentivization genomic donors around the globe to contribute their data toward a future where Alzheimer’s disease is, itself, a forgotten memory.

Recommended